J&J un­corks new Trem­fya da­ta in ul­cer­a­tive col­i­tis as its ri­val awaits an FDA de­ci­sion

While J&J’s Janssen pre­vi­ous­ly re­port­ed that rough­ly 60% of mod­er­ate to se­vere ul­cer­a­tive col­i­tis pa­tients re­spond­ed to an IV for­mu­la­tion of Trem­fya, the com­pa­ny’s now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER